Document:

<PAGE>   1
                                                                   EXHIBIT 10.31

        THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND
        HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
        THESE SECURITIES MAY NOT BE OFFERED, SOLD OR TRANSFERRED ABSENT SUCH
        REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT.

                        PLANET POLYMER TECHNOLOGIES, INC.
                     WARRANT TO PURCHASE UP TO A MAXIMUM OF
                          50,000 SHARES OF COMMON STOCK

        In consideration of the sum of good and valuable consideration, the
receipt of which is hereby acknowledged by PLANET POLYMER TECHNOLOGIES, INC., a
California corporation (the "Company"), LBC CAPITAL RESOURCES, INC., (the
"Holder"), is hereby granted the right to purchase at any time from the date
hereof until 5:00 p.m., Pacific Standard Time, on March 20, 2006 (the "First
Expiration Date") up to all or any part of Fifty Thousand (50,000) fully paid
and non-assessable shares of the Company's common stock, without par value
("Common Stock").

        1. EXERCISE OF WARRANT. This Warrant is exercisable at a price of
$4.1625 per share of Common Stock issuable hereunder (the "Exercise Price")
payable in cash or by certified or official bank check. Upon surrender of this
Warrant, together with a subscription form substantially in the form of "Exhibit
A" hereto duly executed, together with payment of the Exercise Price for the
shares of Common Stock purchased, at the principal executive offices of the
Company, 9985 Business Park Avenue, Suite A, San Diego, California, 92131, or at
such other office as the Company may designate by notice in writing, the Holder
shall be entitled to receive, as promptly as practicable after surrender of the
Warrant, a certificate or certificates for the shares of Common Stock so
purchased. Upon exercise of this Warrant as set forth in the preceding sentence,
the Holder shall be deemed to be the holder of record of the shares of Common
Stock issuable upon such exercise.

The purchase rights represented by this Warrant are exercisable at the option of
the Holder hereof, in whole or in part (but not as to fractional shares of the
Common Stock), during any period in which this Warrant may be exercised as set
forth above. In the case of the purchase of less than all the shares of Common
Stock purchasable under this Warrant, the Company shall cancel this Warrant upon
the surrender hereof and shall execute and deliver a new Warrant of like kind
for the balance of the shares of Common Stock purchasable hereunder.

        2. ISSUANCE OF STOCK CERTIFICATES. The issuance of certificates for
shares of Common Stock upon the exercise of this Warrant shall be made without
charge to the Holder hereof of any tax which may be payable in respect to the
issuance thereof, and such certificates shall (subject to the provisions of
Sections 3 and 5 hereof) be issued in the name of, or in such names as may be
directed by, the Holder hereof; provided, however, that the Company shall not be
required to pay any tax which may be payable in respect to any transfer involved
in the issuance and delivery of any such certificate in a name other than that
of the Holder and the Company shall not be required to issue or deliver such
certificates unless or until the person or

                                       1
<PAGE>   2

persons requesting the issuance thereof shall have paid to the Company the
amount of such tax or shall have established to the satisfaction of the Company
that such tax has been paid, and provided that the issuance of certificates for
such shares of Common Stock shall not violate the securities laws.

        3. TRANSFER, DIVISION AND COMBINATION.

           3.1 Transfer. Subject to compliance with Section 8, the Holder of
this Warrant may transfer this Warrant at any time to any subsidiary or
affiliate of the Holder. Transfer of this Warrant and all rights hereunder, in
whole or in part, shall be registered on the books of the Company to be
maintained for such purpose, upon surrender of this Warrant at the principal
office of the Company or the office or agency designated by the Company,
together with a written assignment of this Warrant substantially in the form of
Exhibit B hereto duly executed by Holder or its agent or attorney and funds
sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall, subject
to Section 8, execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees and in the denomination specified in such instrument of
assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A
Warrant, if properly assigned in compliance with Section 8, may be exercised by
a new Holder for the purchase of shares of Common Stock without having a new
Warrant issued.

           3.2 Division and Combination. Subject to Section 8, this Warrant may
be divided or combined with other Warrants upon presentation hereof at the
aforesaid office or agency of the Company, together with a written notice
specifying the names and denominations in which new Warrants are to be issued,
signed by Holder or its agent or attorney. Subject to compliance with Section
3.1 and with Section 8, as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or
Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice.

           3.3 Expenses. The Company shall prepare, issue and deliver at its own
expense (other than transfer taxes) the new Warrant or Warrants under this
Section.

           3.4 Maintenance of Books. The Company agrees to maintain, at its
aforesaid office or agency, books for the registration and the registration of
transfer of the Warrants.

        4. EXERCISE PRICE. The exercise price of this Warrant shall be $4.1625
per share of Common Stock.

        5. REGISTRATION AND REGISTRATION RIGHTS.

           5.1 Restricted Securities. The shares of Common Stock issuable upon
exercise of this Warrant (the "Warrant Shares") have not been registered under
the Securities Act of 1933, as amended (the "Securities Act").

                                       2
<PAGE>   3

        Except as otherwise provided in this Section, upon exercise, in part or
in whole, of this Warrant, the Warrant Shares shall bear the following legend:

               "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
               REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR
               APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN
               ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD,
               TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE
               REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
               ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, OR
               AN OPINION OF COUNSEL IN FORM, SUBSTANCE AND SCOPE REASONABLY
               ACCEPTABLE TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER
               SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD
               PURSUANT TO RULE 144 UNDER SAID ACT. ANY SUCH OFFER, SALE,
               ASSIGNMENT OR TRANSFER MUST ALSO COMPLY WITH APPLICABLE STATE
               SECURITIES LAWS."

           5.2 Definitions. For purposes of Section 5.

               (a) The term "Commission" means the Securities and Exchange
Commission;

               (b) The term "Exchange Act" means the Securities Exchange Act of
1934, as amended;

               (c) The term "register," "registered," and "registration" refer
to a registration effected by preparing and filing a registration statement in
compliance with the Securities Act and the declaration or ordering of
effectiveness of such registration statement;

               (d) The term "Registrable Securities" means Common Stock issuable
or issued upon exercise of Warrants to purchase Common Stock of the Company
outstanding as of the filing of any registration statement subject to the
provisions of Section 5.3;

               (e) The term "Holder" means any investor holding Registrable
Securities and any other person holding Registrable Securities to whom these
registration rights have been transferred pursuant to Sections 3 and 5; and

               (f) The term "Securities Act" means the Securities Act of 1933,
as amended.

                                       3
<PAGE>   4

           5.3 Company Registration.

               (a) If the Company at any time proposes to file on its behalf
and/or on behalf of any of its security holders (the "demanding security
holders") a registration statement under the Securities Act on any form (other
than a Registration Statement on Form S-4 or S-8 or any successor form for
securities to be offered in a transaction of the type referred to in Rule 145
under the Securities Act or to employees of the Company pursuant to any employee
benefit plan, respectively) for the general registration of securities to be
sold for cash with respect to its Common Stock or any other class of equity
security (as defined in Section 3(a)(11) of the Exchange Act) of the Company, it
will give written notice to all holders of Warrants or Warrant Stock at least
ten (10) days before the initial filing with the Commission of such registration
statement, which notice shall set forth the intended method of disposition of
the securities proposed to be registered by the Company. The notice shall offer
to include in such filing the aggregate number of shares of Warrant Stock, and
the number of shares of Common Stock for which this Warrant is exercisable, as
such holders may request.

               (b) Each holder of any such Warrants or any such Warrant Stock
desiring to have Warrant Stock registered under this Section 5.3 shall advise
the Company in writing within ten (10) days after the date of receipt of such
offer from the Company, setting forth the amount of such Warrant Stock for which
registration is requested. The Company shall thereupon include in such filing
the number of shares of Warrant Stock for which registration is so requested,
subject to the paragraph 5.3 (c) below, and shall use its best efforts to effect
registration under the Securities Act of such shares.

               (c) If the registration of which the Company gives notice is for
a registered public offering involving an underwriting, the Company shall so
indicate in the notice given pursuant to Section 5.3(a). In such event the right
of any Holder to registration pursuant to this Section 5.3 shall be conditioned
upon such Holder's agreeing to participate in such underwriting and in the
inclusion of the securities of the Holder to be so registered in the
underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall (together with the Company and
the other holders distributing their securities through such underwriting) enter
into an underwriting agreement in customary form with the underwriter or
underwriters selected for such underwriting by the Company. Notwithstanding any
other provision of this Section 5.3, if the underwriter determines that
marketing factors require a limitation of the number of shares to be
underwritten, the underwriter may exclude some or all of the securities of the
Holders from such registration and underwriting (hereinafter an "Underwriter
Cutback"). In the event of an Underwriter Cutback, the Company shall so advise
the Holders distributing their securities through such underwriting, and the
number of Registrable Securities that may be included in the registration and
underwriting shall be allocated among the Holder in proportion, as nearly as
practicable, to the respective amounts of Registrable Securities held by such
Holders at the time of filing the registration statement; provided that in no
event shall the Company be required to include in the registration less than one
thousand (1,000) shares held by any Holder. If any Holder disapproves of the
terms of any such underwriting, such Holder may elect to withdraw therefrom by
written notice to the Company and the underwriter. Any securities excluded or
withdrawn from such underwriting

                                       4
<PAGE>   5

shall be withdrawn from such registration. Except as otherwise provided in
Section 5.5, all expenses of such registration shall be borne by the Company.

           5.4 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to Section 5 that the
Holders shall furnish to the Company such information regarding them, the
Registrable Securities held by them, and the intended method of disposition of
such securities as the Company shall reasonably request and as shall be required
in connection with the action to be taken by the Company.

           5.5 Company Registration Expenses. All expenses incurred in complying
with Section 5, including, without limitation, all registration and filing fees,
printing expenses, fees and disbursements of counsel for the Company, the
reasonable fees and expenses of one counsel for the selling security holders
(selected by those holding a majority of the shares being registered), expenses
of any special audits incident to or required by any such registration and
expenses of complying with the securities or blue sky laws of any jurisdictions
pursuant of Section 5, shall be paid by the Company, except that the Company
shall not be liable for any fees, discounts or commissions to any underwriter or
any fees or disbursements of counsel for any underwriter in respect of the
securities sold by such Holder of Warrant Stock.

           5.6 Delay of Registration. No Holder shall have any right to take any
action to restrain, enjoin, or otherwise delay any registration as the result of
any controversy that might arise with respect to the interpretation or
implementation of this Section 5.

           5.7 Indemnification. In the event any Registrable Securities are
included in a registration statement under Section 5:

               (a) To the extent permitted by law, the Company will indemnify
and hold harmless each Holder, each of such Holder's directors and officers and
each other person who is requesting or joining in a registration, any
underwriter (as defined in the Securities Act) for it, and each other person, if
any, who controls such Holder or underwriter within the meaning of the
Securities Act, against any losses, claims, damages, or liabilities, joint or
several, to which they may become subject under the Securities Act or otherwise,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereof) arise out of or are based on any untrue or alleged untrue statement of
any material fact contained in such registration statement, including any
preliminary prospectus or final prospectus contained herein or any amendments or
supplements thereto, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated herein, or
necessary to make the statements therein not misleading or arise out of any
violation by the Company of any rule or regulation promulgated under the
Securities Act applicable to the Company and relating to action or inaction
required of the Company in connection with any such registration; and will
reimburse each such Holder, director, officer, participating person,
underwriter, or controlling person for any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss,
claim, damage, liability, or action; provided, however, that the indemnity
agreement contained in this Section 5.7(a) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability, or action if such
settlement is effected without the consent of the Company nor shall the Company
be liable in any such case for any

                                       5
<PAGE>   6

such loss, claim, damage, liability, or action to the extent that it arises out
of or is based upon an untrue statement or alleged untrue statement or omission
or alleged omission made in connection with such registration statement,
preliminary prospectus, final prospectus, or amendments or supplements thereto,
in reliance upon and in conformity with written information furnished expressly
for use in connection with such registration by any such Holder, director,
officer, other participating person, underwriter, or controlling person. Such
indemnity shall remain in full force and effect regardless of any investigation
made by or on behalf of such Holder or such director, officer participating
person underwriter or controlling person, and shall survive the transfer of such
Securities by such Holder.

               (b) To the extent permitted by law, each Holder requesting or
joining in a registration will indemnify and hold harmless the Company, each of
its directors each of its officers who has signed the registration statement,
each person, if any, who controls the Company within the meaning of the
Securities Act, and each agent and any underwriter for the Company (within the
meaning of the Securities Act) against any losses, claims, damages, or
liabilities to which the Company or any such director, officer, controlling
person, agent, or underwriter may become subject, under the Securities Act or
otherwise, insofar as such losses, claims, damages, or liabilities (or actions
in respect thereto) arise out of or are based upon any untrue statement or
alleged untrue statement of any material fact contained in such registration
statement, including any preliminary prospectus or final prospectus contained
herein or any amendments or supplements thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading,
in each case to the extent, but only to the extent, that such untrue statement
or alleged untrue statement or omission or alleged omission was made in such
registration statement, preliminary or final prospectus, or amendments or
supplements thereto, in reliance upon and in conformity with written information
furnished by such Holder expressly for use in connection with such registration;
and each such Holder will reimburse any legal or other expenses reasonably
incurred by the Company or any such director, officer, controlling person,
agent, or underwriter in connection with investigating or defending any such
loss, claim, damage, liability, or action; provided, however, that the indemnity
agreement contained in this Section 5.7 (b) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability, or action if such
settlement is effected without the consent of such Holder (which consent shall
not be unreasonably withheld).

               (c) Promptly after receipt by an indemnified party under this
section of notice of the commencement of any action, such indemnified party
will, if a claim in respect thereof is to be made against any indemnifying party
under this section, notify the indemnifying party in writing of the commencement
thereof and the indemnifying party shall have the right to participate in and,
to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with counsel
mutually satisfactory to the parties. The failure to notify an indemnifying
party promptly of the commencement of any such action, if prejudicial to his
ability to defend such action, shall relieve such indemnifying party of any
liability to the indemnified party under this section, but the omission so to
notify the indemnifying party will not relieve him of any liability that he may
have to any indemnified party otherwise than under this section.

                                       6
<PAGE>   7

           5.8 Reports Under the Exchange Act. With a view to making available
to the Holders the benefits of Rule 144 promulgated under the Securities Act and
any other rule or regulation of the Commission that may at any time permit a
Holder to sell securities of the Company to the public without registration, the
Company agrees to use its best efforts to:

               (a) make and keep public information available, as those terms
are understood and defined in Rule 144, at all times subsequent to the date
hereof;

               (b) file with the Commission in a timely manner all reports and
other documents required of the Company under the Securities Act and the
Exchange Act; and

               (c) furnish to any Holder so long as such Holder owns any of the
Registrable Securities forthwith upon request a written statement of the Company
that it has complied with the reporting requirements of rule 144, and of the
Securities Act and the Exchange Act (at any time after it has become subject to
such reporting requirements), a copy of the most recent annual or quarterly
report of the Company, and such other reports and documents so filed by the
Company as may be reasonably requested in availing any Holder of any rule or
regulation of the Commission permitting the selling of any such securities
without registration.

           5.9 Lockup Agreement. In consideration for the Company agreeing to
its obligations under this Section 5, each Holder agrees in connection with any
registration of the Company's securities that, upon the request of the Company
or the underwriters managing any underwritten offering of the Company's
securities, not to sell, make any short sale of, loan, grant any option for the
purchase of, or otherwise dispose of any Warrants or Warrant Stock (other than
those included in the registration) without the prior written consent of the
Company or such underwriters, as the case may be, for such period of time (not
to exceed one hundred eighty (180) days) from the effective date of such
registration as the Company or the underwriters may specify.

        6. ADJUSTMENTS OF PURCHASE PRICE AND NUMBER OF SHARES.

           6.1 Subdivision and Combination. In case the Company shall at any
time subdivide or combine the outstanding shares of Common Stock, the Exercise
Price shall forthwith be proportionately decreased in the case of subdivision or
increased in the case of combination.

           6.2 Adjustment in Number of Shares. Upon each adjustment of the
Exercise Price pursuant to the provisions of this Section 6 (including 6.4
through 6.7 below), the number of shares of Common Stock issuable upon the
exercise of each Warrant shall be adjusted to the nearest full share of
multiplying the Exercise Price in effect immediately prior to such adjustment by
the number of shares of Common Stock issuable upon exercise of the Warrant
immediately prior to such adjustment and dividing the product so obtained by the
adjusted Exercise Price.

           6.3 Anti-Dilution Provisions. The Exercise Price in effect at any
time and the number and kind of securities purchasable upon the exercise of this
Warrant shall also be subject

                                       7
<PAGE>   8

to adjustment from time to time upon the happening of any of the events set
forth in Sections 6.4 through 6.7.

           6.4 In the event the Company shall issue or sell any shares of Common
Stock (except as provided in Section 6.7) for a consideration per share less
than the Exercise Price in effect immediately prior to such issue or sale, then
the Exercise Price in effect immediately prior to such issue or sale shall be
reduced to such lesser price (calculated to the nearest cent) as shall be
determined by multiplying the Exercise Price in effect immediately prior thereto
by a fraction, the numerator of which shall be the sum of: (i) the number of
shares of Common Stock outstanding immediately prior to the issuance or sale of
such additional share; and (ii) the number of shares of Common Stock which the
aggregate consideration received for the issuance or sale of such additional
shares would purchase at the Exercise Price then in effect, and the denominator
of which shall be the number of shares of Common Stock outstanding immediately
after the issuance or sale of such additional shares. For purposes of this
Section, all shares of Common Stock issuable upon exercise of outstanding
options and warrants, and all shares of Common Stock issuable upon exercise of
this Warrant, shall be deemed to be outstanding.

           6.5 For the purposes of Section 6.4 above, the following
subparagraphs (a) to (d), inclusive, shall be applicable:

               (a) If at any time the Company shall issue or sell any rights to
subscribe for, or any rights or options to purchase, Common Stock or any stock
or other securities convertible into or exchangeable for Common Stock (such
convertible or exchangeable stock or securities being hereinafter called
"Convertible Securities"), whether or not such rights or options or the right to
convert or exchange any such Convertible Securities shall be immediately
exercisable, and the price per share for which Common Stock shall be issuable
upon the exercise of such rights or options or upon conversion or exchange of
such Convertible Securities (determined by dividing: (1) the total amount, if
any, received or receivable by the Company as consideration for the granting of
such rights or options, plus the minimum aggregate amount of additional
consideration payable to the Company upon the exercise of such rights or
options, plus, in the case of any such rights or options which shall relate to
Convertible Securities, the minimum aggregate amount of additional
consideration, if any, payable upon the issue or sale of such Convertible
Securities and upon the conversion or exchange thereof, by (2) the total number
of shares of Common Stock issuable upon the exercise of such rights or options
or upon the conversion or exchange of all such Convertible Securities issuable
upon the exercise of such rights or options) shall be less than the Exercise
Price in effect immediately prior to the time of the issue or sale of such
rights or options, then the total number of shares of Common Stock issuable upon
the exercise of such rights or options or upon conversion or exchange of the
total amount of such Convertible Securities issuable upon the exercise of such
rights or options shall (as of the date of granting of such rights or options)
be deemed to be outstanding and to have been issued for such price per share,
and except as provided in Section 6.6, no further adjustments of the Exercise
price shall be made upon the actual issue of such Common Stock or of such
Convertible Securities, upon the exercise of such rights or upon the actual
issue of such Common Stock upon conversion or exchange of such Convertible
Securities.

                                       8
<PAGE>   9

               (b) If at any time the Company shall issue or sell or any
Convertible Securities, whether or not the rights to exchange or convert
thereunder shall be immediately exercisable, and the price per share for which
Common Stock shall be issuable upon such conversion or exchange (determined by
dividing (1) the total amount received or receivable by the Company as
consideration for the issue and sale of such Convertible Securities, plus the
minimum aggregate amount of additional consideration, if any payable to the
Company upon the conversion or exchange thereof, by (2) the total number of
shares of Common Stock distributable upon the conversion or exchange of all such
Convertible Securities) shall be less than the Exercise Price in effect
immediately prior to the time of such issue or sale, and the total number of
shares of Common Stock issuable upon conversion or exchange of all such
Convertible Securities shall (as of the date of the issue or sale of such
Convertible Securities) be deemed to be outstanding and to have been issued for
such price per share, and, except as provided in Section 6.6 no further
adjustments of the Exercise Price shall be made upon the actual issue of such
Common Stock upon conversion or exchange of such Convertible Securities. In
addition, if any issue or sale of such Convertible Securities shall be made upon
exercise of any rights to subscribe for or to purchase or any option to purchase
any such Convertible Securities for which adjustments of the Exercise Price
shall have been or shall be made pursuant to other provisions of this Section
6.5, no further adjustments with the Exercise Price shall be made by reason of
such issue or sale.

               (c) If at any time any shares of Common Stock or Convertible
Securities or any rights or options to purchase any such Common Stock or
Convertible Securities shall be issued or sold for cash, the consideration
received therefore shall be deemed to be the amount actually received by the
Company therefore, after deduction therefrom of any expenses incurred or any
underwriting commissions or concessions or discounts paid or allowed by the
Company in connection therewith. In case any shares of Common Stock or
Convertible Securities or any rights or options to purchase any such Common
Stock or Convertible Securities shall be issued or sold for a consideration
other than cash, the amount of the consideration other than cash actually
received by the Company shall be deemed to be the fair value of such
consideration as determined by the Board of Directors, after deduction therefrom
of any expenses incurred or any underwriting commission or concessions or
discounts paid or allowed by the Company in connection therewith. In case any
shares of Common Stock or Convertible Securities or any rights or options to
purchase any such Common Stock or Convertible Securities shall be issued in
connection with any merger or another corporation into the Company, the amount
of consideration therefore shall be deemed to be the greater of the fair market
value of the shares issued in connection with the merger after taking into
account the effects of the merger or the fair market value of the net assets of
such merged corporation as determined by the Board of Directors after deducting
therefrom all cash and other consideration (if any) paid by the Company in
connection with such merger.

               (c) The number of shares of Common Stock outstanding at any given
time shall not include shares owned or held by or for the account of the
Company, provided that such shares are neither issued, sold or otherwise
distributed by the Company.

           6.6 If the purchase or exercise price provided for in any right or
option referred to in

                                       9
<PAGE>   10

Section 6.5, or the rate at which any Convertible Securities referred to in
Section 6.5(a) or (b) shall be convertible into or exchangeable for Common
Stock, shall change or a different purchase or exercise price or rate shall
become effective at any time or from time to time (including any change
resulting from termination of such right, option or convertible security), the,
upon such change becoming effective, the Exercise Price then in effect hereunder
shall forthwith be increased or decreased to such Exercise Price as would have
been obtained had the adjustments made upon the granting or issuance of such
rights or options or Convertible Securities been made upon the basis of: (a) the
issuance of the number of shares of Common Stock theretofore actually delivered
upon the exercise of such options or rights or upon the conversion or exchange
of such Convertible Securities for the considerations received therefore; and
(b) the granting or issuance at the time of such change of any such options,
rights or Convertible Securities then still outstanding for the consideration,
if any, received by the Company therefor and to be received on the basis of such
changed price.

           6.7 The Company shall not be required to make any adjustment to the
Exercise Price in the case of:

               (a) the granting, after the date hereof, by the Company of stock
options under the Company's 1995 Stock Option Plan and 2000 Stock Incentive
Plan, so long as the shares of Common Stock underlying such options are covered
by the One Million (1,000,000) shares currently reserved for issuance under such
Plans as of the date hereof; or

               (b) the issuance of shares of Common Stock, pursuant to the
exercise of the options referred to in Section 6.7 (a) above; and

               (c) shares of Common Stock issued upon the exercise or
conversion, as the case may be, or under the dividend provisions thereof, if
any, of any options, warrants, preferred stock, convertible securities or other
rights to purchase Common Stock which options, warrants, preferred stock,
convertible securities or other rights are issued and outstanding on the date
hereof.

           6.8 Reclassification, Consolidation, Merger, Etc., In case of any
reclassification or change of the outstanding shares of Common Stock (other than
a change in par value to no par value, or from no par value to par value, or as
a result of a subdivision or combination), or in the case of any consolidation
of the Company with, or merger of the Company into, another corporation (other
than a consolidation or merger in which the Company is the surviving corporation
and which does not result in any reclassification or change of the outstanding
shares of Common Stock, except a change as a result of a subdivision or
combination of such shares or conveyance to another corporation of the property
of the Company as an entirety), the Holder of this Warrant shall thereafter have
the right to purchase the kind and number of shares of stock and other
securities and property receivable upon such reclassification, change,
consolidation, merger, sale or conveyance at an aggregate price equal to the
product of: (x) the number of shares issuable upon exercise of this Warrant and
(y) the Exercise Price in effect immediately prior to the record date for such
reclassification, change, consolidation, merger, sale or conveyance as if such
Holder had exercised this Warrant prior to such record date.

                                       10
<PAGE>   11

           6.9 Approval and Notice of Adjustment in Exercise Price. Any
adjustment of the Exercise Price made pursuant to this Section 6 shall be made
or approved by the Company's independent public accountants at the time of such
adjustment.

        7. FINANCIAL AND BUSINESS INFORMATION.

           7.1 Annual Information. The Company will deliver to each Holder as
soon as practicable after the end of fiscal year of the Company, and in any
event within ninety (90) days thereafter, (a) one copy of an unaudited
consolidated balance sheet of the Company and its subsidiaries as at the end of
such year, and (b) unaudited consolidated statements of income, retained
earnings and changes in financial position of the Company and its subsidiaries
for such year; setting forth in each case in comparative form the figures for
the corresponding periods in the previous fiscal year; all prepared in
accordance with GAAP, and which audited financial statements shall be
accompanied by: (i) an opinion thereon of the independent certified public
accountants regularly retained by the Company, or any other form of independent
certified public accountants of recognized national standing selected by the
Company; and (ii) a report of such independent certified public accountants
confirming any adjustment made pursuant to Section 6 during such year.

        8. REPRESENTATIONS OF HOLDER.

           8.1 Acquisition of Warrant for Personal Account. The Holder
represents and warrants that it is acquiring the Warrant solely for its account
for investment and not with a view to or for sale or distribution of said
Warrant for any part thereof. The Holder also represents that the entire legal
and beneficial interests of the Warrant and Warrant Stock is being acquired for,
and will be held for, its account only.

           8.2 Securities Are Not Registered.

               (a) The Holder recognizes that this Warrant and Warrant Stock
being acquired by it must be held indefinitely unless they are subsequently
registered under the Act or an exemption from such registration is available.
The Holder recognizes that, except as set forth in Section 5 hereof, the Company
does not have any obligation to register this Warrant or the Warrant Stock or to
comply with any exemption from such registration.

               (b) The Holder is aware that neither this Warrant nor the Warrant
Stock may be sold pursuant to Rule 144 adopted under the Act unless certain
conditions are met and until the Holder has held the Warrant Stock for at least
one year. Among the conditions for use of rule 144 is the availability of
current information to the public about the Company. The Holder understands that
the Company has not made such information available and has no present plans to
do so.

               (c) The Holder represents and warrants that it is an "accredited
investor" as such term is defined in rule 501(a) under the Act. Specifically,
the Holder represents and warrants that it is either a corporation or
partnership, not formed for the specific purpose of acquiring securities of the
Company, with total assets in excess of $5,000,000.

                                       11
<PAGE>   12

           8.3 Disposition of Warrant and Warrant Stock. The Holder further
agrees not to make any disposition of all or any part of this Warrant or the
Warrant Shares in any event unless and until:

               (a) The Company shall have received a letter secured by the
Holder from the Securities and Exchange Commission stating that no action will
be recommended to the Commission with respect to the proposed proposition; or

               (b) There is then in effect a registration statement under the
Act covering such proposed disposition and such disposition is made in
accordance with said registration statement; or

               (c) The Holder shall have notified the Company of the proposed
disposition and shall have furnished the Company with a detailed statement of
the circumstances surrounding the proposed disposition, the Holder shall have
furnished the Company with an opinion of counsel for the Holder to the effect
that such disposition will not require registration of such Warrant or shares
under the Act, and such opinion of counsel for the Holder shall have been
concurred in by the Company's counsel and the Company's counsel and the Company
shall advise the Holder of such concurrence; or

               (d) Notwithstanding the provisions of paragraphs (a), (b) and (c)
above, no such Securities and Exchange Commission letter, registration statement
or opinion of counsel shall be required: (i) for any transfer of this Warrant or
any shares issuable upon exercise of this Warrant in compliance with SEC Rule
144 or 144A; or (ii) for any transfer of this Warrant or shares issuable upon
exercise of this Warrant by a Holder that is a partnership or a corporation to
(A) a partner of such partnership or corporation; (B) a retired partner or
shareholder; or (iii) the transfer by gift, will or intestate succession by any
Holder to his or her spouse or lineal descendents or ancestors or any trust for
any of the foregoing.

        9. EXCHANGE AND REPLACEMENT OF WARRANT. This Warrant is exchangeable
without expense, upon the surrender hereof by the registered Holder at the
principal executive office of the Company, for a new Warrant of like kind and
date representing in the aggregate the right to purchase the same number of
shares as are purchasable hereunder in such denominations and in the name(s) of
such assignee(s) as shall be designated by the registered Holder hereof at the
time of such surrender.

        Upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft or destruction of this Warrant, of indemnity or security
reasonably satisfactory to it, and reimbursement to the Company of all
reasonable expenses incidental thereto, and upon surrender and cancellation of
this Warrant, if mutilated, the Company will make and deliver a new Warrant of
like kind, in lieu of this Warrant.

        10. FRACTIONAL SHARES. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. With
respect to any fraction of a share called upon any exercise thereof, the Company
shall pay to the Holder an amount in equal to

                                       12
<PAGE>   13

such fraction multiplied by the current market value of a share of Common Stock,
as determined in good faith by the Board of Directors of the Company.

        11. RESERVATION AND LISTING OF SHARES. The Company shall at all times
reserve and keep available out of its authorized shares of Common Stock, solely
for the purpose of issuance upon the exercise of this Warrant, such number of
shares of Common Stock as shall be issuable upon the exercise hereof. The
Company covenants and agrees that, upon exercise of this Warrant and payment of
the Exercise Price therefore, all shares of Common Stock issuable upon such
exercise shall be duly and validly issued, fully paid and non-assessable,
provided that the Exercise Price per share shall equal or exceed the par value
of the Common Stock. As long as the Warrant shall be outstanding, the Company
shall use its best efforts to cause all shares of Common Stock issuable upon the
exercise of the Warrant to be listed (subject to official notice of issuance) on
all securities exchanges on which the Common Stock may then be listed.

        12. CERTIFICATE AS TO ADJUSTMENTS. Upon the occurrence of each
adjustment or readjustment of the Exercise Price, the Company, at its expense,
shall promptly compute such adjustment or readjustment in accordance with the
terms hereof and prepare and furnish to the Holder a certificate of the chief
financial officer of the Company setting forth such adjustment or readjustment
and showing in detail the facts upon which such adjustment or readjustment is
based. The Company shall, upon the written request at any time of the Holder,
furnish to the Holder a like certificate setting forth: (i) such adjustments and
readjustments; (ii) the Exercise Price at the time in effect; and (iii) the
number of shares of Common Stock and the amount, if any, of other property which
at the time would be received upon the exercise of this Warrant.

        13. RIGHTS OF WARRANT HOLDERS. Nothing contained in this Warrant shall
be construed as conferring upon the Holder hereof the right to vote or to
consent or to receive notice as a shareholder in respect of any meetings or
shareholders for the election of directors or any other matter, or as having any
rights whatsoever as a shareholder of the Company.

        14. NOTICES. All notices, requests, consents and other communications
hereunder shall be deemed to have been duly made when delivered in person, or
mailed by registered or certified mail, return receipt requested:

            (a) If to the registered Holder or Holders of this Warrant, to the
address of such Holder as shown on the books of the Company; or

            (b) If to the Company, to the address set forth on the first page of
this Warrant or to such other address as the Company may designate by notice to
the Holders.

        15. REMEDIES. Each holder of Warrant and Warrant Shares, in addition to
being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under Section 5
of this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions
of Section 5 of this Warrant and hereby agrees to waive the defense in any
action for specific performance that a remedy at law would be adequate.

                                       13
<PAGE>   14

        16. AMENDMENT. This Warrant and all other Warrants may be modified or
amended or the provisions hereof waived with the written consent of the Company
and the Holder or Holders, provided that no such Warrant may be modified or
amended to reduce the number of shares of Common Stock for which such Warrant is
exercisable or to increase the price at which such shares may be purchased upon
exercise of such Warrant (before giving effect to any adjustment as provided
therein) without the prior written consent of the Holder thereof.

        17. SEVERABILITY. Wherever possible, each provision of this Warrant
shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Warrant shall be prohibited by or
invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such
provision or the remaining provisions of this Warrant.

        18. SUCCESSORS. All the covenants, agreements, representations and
warranties contained in this Warrant shall bind the parties hereto and their
respective heirs, executors, administrators, distributees, successors and
assigns.

        19. HEADINGS. The Section headings in this Warrant are inserted for
purposes of convenience only and shall have no substantive effect.

        20. LAW GOVERNING. This Warrant shall be construed and enforced in
accordance with, and governed by, the laws of the State of California.

        WITNESS the seal of the Company and the signature of its duly authorized
officer.

                                  PLANET POLYMER TECHNOLOGIES, INC.

DATED:  March 20, 2001            By:___________________________________________
                                     Richard C. Bernier, Chief Executive Officer

                                       14
<PAGE>   15

                                    EXHIBIT A

                                SUBSCRIPTION FORM

                    (To be Executed by the Registered Holder
                        in Order to Exercise the Warrant)

        The undersigned hereby irrevocably elects to exercise the right to
purchase ______ shares of Common Stock of Planet Polymer Technologies, Inc.
covered by the Warrant to which this Exhibit A is attached, according to the
conditions of such Warrant, and herewith makes payment of the Exercise Price of
such shares in full.

                     INSTRUCTIONS FOR REGISTRATION OF STOCK

NAME ____________________________

ADDRESS _________________________

                                            ____________________________________
                                            Signature

Dated: _________________________

                                       1
<PAGE>   16

                                     ANNEX B

                                 ASSIGNMENT FORM

        FOR VALUE RECEIVED, the undersigned registered owner of the Warrant to
which this Exhibit B is attached hereby sells, assigns and transfers unto the
Assignee named below all of the rights of the undersigned under such Warrant,
with respect to the number of shares of Common Stock set forth below.

Name and Address of Assignee                 No. of Shares of Common Stock
----------------------------                 -----------------------------

and does hereby irrevocably constitute and appoint ________________
attorney-in-fact to register such transfer on the books of Planet Polymer
Technologies Inc. maintained for the purpose, with full power of substitution in
the premises.

Dated: ______________________               ____________________________________
                                            Signature

                                       1<PAGE>   1

                                                                   EXHIBIT 10.26

                                                                ----------------
                                                                REDACTED VERSION
                                                                ----------------

                              SUBLICENSE AGREEMENT

This License Agreement ("Agreement"), is made and entered into this 15th day of
May, 1997 ("Effective Date"), by and between

                            Boehringer Mannheim GmbH,
                              a German corporation
         having its principal place of business at Sandhofer Strasse 116
                                 Postfach 310120
                            D-68298 Mannheim Germany
                                 ("Boehringer")

                                       and

                                   NeoRx Co.,
                             an American corporation
       having its principal place of business at 410 West Harrison Street
                            Seattle, Washington 98119
                                   ("NeoRx").

<PAGE>   2

WHEREAS:

Biogen Inc. has granted Boehringer the exclusive right to make, have made, use,
market and sell LICENSED PRODUCTS which right is covered by the U.S. Patents
Nos. 5,168,049 and 5,272,254 owned by Biogen Inc., and

NeoRx is interested in making, using, selling and having sold LICENSED PRODUCTS,
for its PRETARGETING TECHNOLOGY, and

BM is willing to grant NeoRx sublicense to make, have made, use, sell and have
sold LICENSED PRODUCTS in the FIELD.

ARTICLE I - DEFINITIONS

1.1   LICENSED PATENTS

      The term "Licensed Patents" shall mean the Biogen, Inc. US Patent Nos.
      5,168,049 and 5,272,254 (licensed by Boehringer from Biogen), and any
      other patent owned or controlled by Boehringer relating to [*] and the
      patents issued therefrom.

[*]   DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

1.2   LICENSED PRODUCTS

      The term "Licensed Products" shall mean [*].

1.3   FIELD

      "Field" shall mean all applications of NeoRx's proprietary Pretargeting
      Technology.

1.4   PRETARGETING TECHNOLOGY

      "Pretargeting Technology" means products and processes involving target
      site localization in a patient through administration of a targeting agent
      [*].

ARTICLE II - LICENSE GRANT

2.1   GRANT OF LICENSE

      Boehringer hereby grants to NeoRx an exclusive sublicense to make, have
      made, use, sell, and have sold Licensed Products in the Field.

<PAGE>   3

2.2   This sublicense to NeoRx shall include [*], consistent with the License
      Agreement of March 1, 1994 between Biogen and Boehringer [*].

2.2.1 NeoRx shall comply with all government statutes and regulations that
      relate to the Licensed Products including all export regulations.

2.3   [*]

2.4   RIGHTS

      Boehringer represents and warrants that it has the right and power to
      grant to NeoRx the sublicense provided herein.

ARTICLE III - ROYALTY

3.1   INITIAL PAYMENT

      In consideration of the right and license granted hereunder, NeoRx shall
      pay to Boehringer the sum of [*] as an initial payment within fifteen (15)
      days of the Effective Date.

3.2   ANNUAL MAINTENANCE FEE

      NeoRx shall pay to Boehringer an annual maintenance fee of [*] due on the
      anniversary date of this Sublicense Agreement.

3.3   ONE-TIME MILESTONE PAYMENT

      NeoRx shall pay to Boehringer a one-time milestone payment of [*] upon
      approval by the United States Food and Drug Administration of the first
      Pretargeting Product containing Licensed Product, no matter if this
      product is a product of NeoRx or a Sublicensee of NeoRx.

3.4   WITHHOLDING TAX ON CONSIDERATION

      Unless otherwise agreed, all taxes or other governmental charges which
      NeoRx is required to withhold from the initial payment and other payments
      under this Agreement shall be deducted from such payments and an evidence
      of such withholding shall be delivered to Boehringer without undue delay.

                                       2
<PAGE>   4

ARTICLE IV - OBLIGATION OF EXCLUSION OF LIABILITY

4.1   DISCLAIMER OF WARRANTY

      Boehringer makes no representations, conditions or warranties that any of
      the Licensed Patents are valid or enforceable and that any manufacture,
      use, sale or other disposal of the Licensed Products is not an
      infringement of any patent of any third party.

4.2   DISCLAIMER OF LIABILITY

      Boehringer shall be under no liability whatsoever to NeoRx (whether in
      negligence or otherwise) for any expense, loss, damage or injury of any
      kind (including any loss of profit or consequential damage) sustained by
      NeoRx or any third party arising or incurred in connection with the
      manufacture, use, sale or other disposal of Licensed Products or deriving
      directly or indirectly out of the use of the Licensed Patents or otherwise
      arising out of the grant of any rights hereunder, or the provision of any
      information in connection herewith.

4.3   INDEMNIFICATION BY NEORX

      NeoRx shall indemnify Boehringer from and against all claims, demands,
      actions, liabilities and damages made by, or awarded to, any person and
      any costs and expenses thereof arising from, or connected with, the
      design, production, manufacture, use, sale, promotion, or other disposal
      of Licensed Products or the provision or use of the Licensed Patents or
      otherwise arising out of the grant of any rights hereunder.

4.4   INFRINGEMENT BY THIRD PARTIES

      NeoRx shall notify Boehringer forthwith of any infringement or threatened
      infringement of any of the Licensed Patents which shall at any time come
      to its knowledge. NeoRx shall give sufficient cooperation that is legally
      appropriate and within reasonable range to protect Boehringer's rights
      over the Licensed Patents.

ARTICLE V - DURATION, TERMINATION AND MISCELLANEOUS

5.1   TERM

      This Agreement shall commence on the Effective Date and endure and remain
      in full force, unless terminated under the provisions of this Agreement,
      throughout the life of any one of the Licensed Patents.

                                       3
<PAGE>   5

5.1.1 [*] In case Boehringer intends not to maintain the Biogen license,
      Boehringer shall inform NeoRx with six (6) months prior notice.

5.1.2 Boehringer shall have the right to terminate this Agreement and license
      granted hereunder if: NeoRx is in breach or default under this Agreement
      and has not cured such breach of or default within sixty (60) days after
      written notice is sent by Boehringer to NeoRx specifying the nature of
      such breach or default.

5.1.3 NeoRx shall have the right to terminate this Agreement upon ninety (90)
      days written notice to Boehringer, if: (1) Boehringer is in breach or
      default under this Agreement and has not cured such breach or default with
      the aforementioned period or, (2) NeoRx is no longer practicing or using
      the Licensed Patents.

5.1.4 Either Party shall have the right by written notice to the other party to
      terminate this Agreement in the event that the other party shall file for
      prosecution under federal or state Bankruptcy Laws, becomes insolvent or
      makes an assignment for the benefit of creditors, enters or is put into
      voluntary or compulsory liquidation or has its business enjoined or
      ordered into receivership of the equivalent.

5.1.5 Termination shall not affect the provisions as set forth in articles 5.5.

5.2   ENFORCEABILITY

      Should any part of this Agreement be held unenforceable or in conflict
      with the law of any jurisdiction, the validity of the remaining parts or
      provisions shall not be affected by such holding.

5.3   WAIVER

      A waiver of any breach of any provision of this Agreement shall not be
      construed as a continuing waiver of other breaches of the same or other
      provisions of this Agreement.

5.4   ASSIGNMENT

      Neither this Agreement nor any interest herein is assignable or
      transferable by NeoRx without a prior approval of Boehringer. In the event
      that Boehringer will assign or otherwise transfer this Agreement to any
      third party, Boehringer shall notice NeoRx prior to such assignment or
      transference and shall bind the assignee or transferee of this Agreement
      to

                                       4
<PAGE>   6

      the same extent as Boehringer is bound by all of terms and conditions
      hereof.

5.5   CONFIDENTIALITY

5.5.1 Each party shall treat all confidential information received from the
      other party (or its agents or employees), including information regarding
      or relating to NeoRx Patent Rights, and any information derived therefrom,
      (any and all such information to be hereinafter referred to as
      "Proprietary Information") as the confidential and proprietary information
      of the disclosing party.

      As used herein, "Proprietary Information" does not include:

      (i)   information which at the time of disclosure to the receiving party
            is generally available to the public, or which after such disclosure
            becomes generally available to the public by publication or
            otherwise other than as the result of a prohibited disclosure by the
            receiving party;

      (ii)  information that is demonstrated to have been in the receiving
            party's possession prior to the time of disclosure by the disclosing
            party;

      (iii) information that is demonstrated by a preponderance of the evidence
            to have been independently developed by the receiving party's
            personnel without reference to Proprietary Information disclosed by
            the disclosing party; and

      (iv)  information received from a third party unless such information is
            obtained subject to a confidential disclosure agreement.

5.5.2 Except as required by law and as otherwise set forth herein, each party
      agrees (i) to hold in strict confidence and trust and maintain as
      confidential all Proprietary Information of the other party except as
      required by applicable law or regulation including, without limitation,
      applicable securities laws and regulations, (ii) not to disclose any such
      Proprietary Information to any person, except to those employees or legal
      counsel of the receiving party who are required to receive the Proprietary
      Information for the purposes described in this Agreement and who are bound
      by a similar obligation of confidentiality and (iii) to use the
      Proprietary Information only for the purposes described in this Agreement.

5.5.3 Each party agrees that all Proprietary Information disclosed by the other
      party will at all times be and remain the sole property of the disclosing

                                       5
<PAGE>   7

      party and the disclosing party is the sole owner of all patents,
      copyrights and other intellectual property rights and other proprietary
      rights related to the Proprietary Information disclosed by it. Nothing in
      this Agreement shall be construed as granting to the receiving party an
      implied license in, or right or option to license or use any intellectual
      property right (including but not limited to any patent right obtained by
      the disclosing party) relating to the Proprietary Information disclosed by
      it or any right to use such Proprietary Information except as expressly
      provided herein.

5.5.4 Immediately upon the termination of this Agreement, or upon disclosing
      party's request, the receiving party will deliver to the disclosing party
      all Proprietary Information disclosed by the disclosing party and all
      documents and data storage media containing any such Proprietary
      Information and any and all copies thereof, and will delete all such
      Proprietary Information from its documents and data storage media.

5.6   GOVERNING LAW

      This Agreement shall be interpreted and construed, and the legal relations
      created herein shall be determined, in accordance with the substantive
      laws of Germany.

5.7   ARBITRATION

5.7.1 Any dispute, controversy or claim rising out of or relating to this
      Agreement shall be referred to arbitration in accordance with the rules of
      conciliation and arbitration of the Zurich Chamber of Commerce.

5.7.2 The Court of Arbitration shall consist of three arbitrators; each party
      shall nominate one member. The chairman shall be appointed by the
      President of the Zurich Chamber of Commerce in accordance with the
      aforementioned arbitration rules.

5.7.3 The arbitration shall be held at a location to be agreed upon by the
      arbitrators in the English language. Arbitration shall be final and
      binding upon both parties.

5.8   MODIFICATION

      No modification or alteration of this Agreement included this provision
      shall be effective unless they are made in writing and signed by duly
      authorized representatives of the parties.

                                       6
<PAGE>   8

5.9   ENTIRE AGREEMENT

      This Agreement constitutes the entire agreement and understanding between
      the parties and supersedes any prior agreements and understandings with
      respect to the Licensed Patents.

5.10  NOTICES

      Notices required under this Agreement shall be in writing and shall for
      all purposes be deemed to be fully given and received when sent by
      registered mail, postage prepaid, to the respective parties at the
      following addresses:

If to Boehringer

      Boehringer Mannheim GmbH
      Legal Counsel Biochemical Division
      Sandhofer Stra(greek beta)e 116
      Postfach 31 01 20
      68298 Mannheim
      Germany

If to NeoRx

      NeoRx Corporation
      Attention: Anna Wight
      410 West Harrison
      Seattle, WA 98119-4007
      USA

Either party hereto may change its address for the purposes of this Agreement by
giving the other party written notice of its new address.

                                       7
<PAGE>   9

In Witness whereof, the parties have affixed their signatures on the dates
indicated below to two (2) duplicate originals, each of which shall be
considered an original.

Date: May 15, 1997                        Date:

BOEHRINGER MANNHEIM GMBH                  NEORX CORPORATION

By:___________________________________    By:__________________________________
    i. V. Dieter Lingelbach                   John M. Reno, Ph.D.
    V.P. Biochemicals for the Pharm.          V.P. Research & Development
    Ind. Business

By:___________________________________
    i. V. Dr. Claus Schneider
    Senior Director Biochemicals for
    the Pharm. Ind. Business

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]